Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...
Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...
City of Hope National Medical Center, Duarte, California, United States
Emory Proton Therapy Center, Atlanta, Georgia, United States
Winship at Emory Midtown, Atlanta, Georgia, United States
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Sibley Memorial Hospital, Washington, District of Columbia, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Biogenix Molecular LLC, Miami, Florida, United States
XCancer Omaha, Omaha, Nebraska, United States
Westmead Hospital, Sydney, New South Wales, Australia
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Asan Medical Center, Seoul, Korea, Republic of
Severance Hospital, Yonsei University Health System - Division of Infectious Diseases, Seoul, Korea, Republic of
Hospital Universitari Vall d'Hebron - Oncology Dept., Barcelona, Spain
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.